ClinicalTrials.gg
RecruitingNCT07530588DIRECT-CTUpdated Apr 15, 2026

Decentralized Imaging by REmote Computer Tomography for Cerebral Infarct Thrombolysis

An interventional study of Decentralized diagnostics and treatment in Stroke, sponsored by University Hospital of North Norway. Recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The DIRECT-CT trial is designed to test the hypothesis that remote controlled CT scanning combined with real time audio-and video conference (AVC) guided assessment from an experienced hospital stroke team (tele-stroke) at decentralized medical centers (DMC) reduces time to intravenous thrombolytic treatment compared to the standard pathway.

Read the detailed description

Intravenous thrombolysis (IVT) treatment is an effective treatment of disabling acute ischemic stroke (AIS) and leads to improved functional outcomes if administered within 4.5 hours after symptom onset. Since the treatment effect is highly time dependent, it is recommended to give IVT as soon as possible after symptom onset to patients with AIS without contraindications. A CT examination of the head must be performed prior to IVT to exclude intracranial hemorrhage. If an intracerebral hemorrhage (ICH) is detected rapid blood pressure lowering medication should be initiated. As of today, timely delivery of acute stroke treatment is challenging in several parts of Norway due to sparsely populated areas with long geographical distances between hospitals. Patients living in rural areas are at risk of not receiving timely acute stroke treatment. Due to the time sensitive nature of IVT, a decentralized approach to diagnostics and treatment is compelling. However, a CT scanner and medical expertise on acute stroke diagnostics and treatment is not readily available in pre-hospital settings in Norway. Investigators therefore plan to 1) assess the feasibility of widespread implementation of a model with decentralized stroke diagnostics and treatment in rural areas with a stationary CT combined with audio-and video guided support from an experienced stroke team at the local hospital 2) compare treatment access, time metrics and outcomes for stroke patients in the DMC catchment area to patients from similar rural areas without access to decentralized diagnostics and treatment. The risk for patients is minimized through remote controlled CT scanning administered from the local hospital combined with tele-stroke guided assessment by an experienced stroke team and regular simulation trainings. All treatment, including thrombolytic therapy, and monitoring routines are performed according to the hospitals' standard operating procedures (SOP). The primary objective is to compare time from Emergency Medical Communication (EMC) notification to IVT treatment between AIS patients in the intervention group comprising patients from geographical areas with an established service of prehospital stroke diagnostics and treatment at the DMC to the control group comprising patients from similar geographical areas undergoing diagnostics and treatment at their local hospital as per standard pathway.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • Rural
  • Prehospital diagnostics and treatment
  • Remote controlled computer tomography
  • Intravenous thrombolysis
  • District medical center
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's planned enrollment of 52 is close to the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University Hospital of North Norway is the lead sponsor of 152 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients in the catchments areas of the intervention and control group presenting with a clinical suspected diagnosis of stroke within symptom onset within the last 24 hours

Exclusion criteria

Exclusion Criteria:

- Patients presenting with a clinical suspected diagnosis of stroke more than 24 hours after symptom onset

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Participants are patients presenting with acute stroke symptoms in rural districts in Norway. A cockpit solution by Syngo Virtual Cockpit® software for remote control of the stationary CT machine at the DMCs from the nearest stroke center is implemented. The EMC center routes the ambulance to DMC Midt-Troms when it is the nearest. A nurse at DMC and the ambulance personnel performs the clinical examination and positions the patient in the CT machine. Through AVC the examination is overseen by the stroke physician, images are interpreted by a radiologist at UNN, and the decision regarding acute treatment is made by the stroke physician at UNN, Tromsø. If indicated, IVT and blood pressure lowering medication is administered by the nurse at the DMC. Patients resenting with acute stroke symptoms in the catchment area of DMC Midt-Troms (Sørreisa and Senja municipalities) and DMC Sør-Helgeland (Brønnøy and Sømna municipalities) comprise the intervention group.

    Other: Decentralized diagnostics and treatment

  • No intervention
    Control

    1\) Patients presenting with acute stroke symptoms residing in municipalities in Nord-Troms (Nordreisa, Kåfjord, Skjervøy and Kvænangen) and Nordland (Saltdal, Hamarøy, Steigen and Sørfold) from the time of DMC model implementation until end of study. These patients are from areas that are geographically similar to Midt-Troms and Sør-Helgeland with regards to distance to the nearest hospital, but without access to prehospital CT diagnostics and acute stroke treatment.

  • No intervention
    Historical control

    This control group consists of acute stroke patients from the same municipalities (both intervention and control group) presenting with stroke symptoms within a 5 year period prior to the implementation of prehospital diagnostics and treatment at the DMC.

Interventions

  • OtherDecentralized diagnostics and treatment

    The intervention includes admittance to the DMC for initial diagnostic work up and acute treatment (if indicated). Paramedics examine the patient and assess stroke severity by NIHSS and G-FAST scoring overseen by a stroke physician at the local hospital through real time video conference. A remote controlled CT scan of the head is conducted, and the stroke team at the local hospital evaluates results and makes a treatment decision in real-time AVC. If treatment is indicated, this is administered by local personnel at the DMC before initiating transport to the local hospital or the comprehensive stroke center in case of LVO. Patients who are unable to reach the DMC prior to estimated admission time at their local hospital, will be treated at their local hospital as per standard pathway.

    Also known as: Prehospital diagnostics and treatment

06

What researchers measure

Primary outcomes

  1. Time from EMC notification to initiation IVT treatment

    The time from Emergency Medical Communication notification to initiation intravenous thrombolysis treatment in eligible patients

    Time frame: Day 0

Secondary outcomes

  1. Time from admittance to initiation of IVT treatment (door-to-needle time)

    Time from admittance to initiation of IVT treatment (door-to-needle time) in eligible patients

    Time frame: Day 0

  2. Time from admittance to start of blood pressure lowering medication in ICH patients

    Time from admittance to start of blood pressure lowering medication in ICH patients patients

    Time frame: Day 0

  3. Proportion of AIS patients receiving IVT treatment (y/n)

    Proportion of acute ischaemic stroke patients receiving IVT treatment (y/n)

    Time frame: Day 0

  4. Proportion of AIS patients receiving EVT treatment (y/n)

    Proportion of acute ischaemic stroke patients receiving endovascular treatment

    Time frame: Day 0

  5. Proportion of patients achieving early neurological improvement

    Early neurological improvement, defined as a reduction of ≥8 points on the NHISS, or NIHSS score of 0-1 at 24 hours (22-36 h) (y/n)

    Time frame: Day 1

  6. mRS score at 90 days

    functional outcome measured by the modified Rankin Scale score (mRS) at discharge and day 90 (± 2 weeks) • mRS category at day 90 (+/- 2 weeks) * excellent functional outcome (mRS 0-1) at day 90 (+/- 2 weeks) * good functional outcome (mRS 0-2) at day 90 (+/- 2weeks) * poor functional outcome (mRS 5-6) at day 90 (+/- 2 weeks)

    Time frame: Month 3

  7. Proportion of patients with symptomatic intracranial hemorrhage (sICH)

    Proportion of patients with symptomatic intracranial hemorrhage (sICH) complications defined as intracranial hemorrhage on CT/MRI within 36 hours post IVT causally related to an increase of 4 points or more on the NIHSS (y/n)

    Time frame: Day 1

  8. Time from symptom onset to groin puncture time

    Time from symptom onset to groin puncture time in patients undergoing thrombectomy

    Time frame: Day 0

  9. Transportation mode (ground or air ambulance)

    Transportation mode to primary or comprehensive stroke centre

    Time frame: Day 0

  10. Mortality

    Mortality during hospitalization, 30 days, 90 days and 1 year

    Time frame: Year 1

  11. Final diagnosis

    The final discharge diagnosis

    Time frame: Week 2

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 41 months is above that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Apr 15, 2026
StartActual
Jul 17, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07530588
Collaborators
Helgelandssykehuset Hospital Trust, Nordlandssykehuset Hospital Trust, Finnmarkssykehuset HF, UiT The Arctic University of Norway, Innlandet Central Hospital HF, Lillehammer, Oslo University Hospital, Ringerike hospital HF, Hønefoss Norway
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Jul 17, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 15, 2026

Study contacts

Agnethe Eltoft, MD, PhD
Contact
agnethe.eltoft@unn.no
+4797193417
Eivor Logstein, MD
Contact
Eivor.Logstein@Helgelandssykehuset.no
Tor Ingebrigtsen, MD, PhD
study director · University Hospital of North Norway

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion